The Prevalence and Associated Factors of Metabolic Syndrome in Psychiatric Patients at Thammasat University Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To determine the prevalence and associated factors of metabolic syndrome in psychiatric patients
Methods: A descriptive cross-sectional study was conducted among psychiatric outpatients at mental health clinic, between August 1, 2022 and July 31, 2023. The sample consisted of 299 psychiatric outpatients diagnosed with the following principle disorders: psychotic disorders, bipolar disorders, depressive disorders, and anxiety disorders. Metabolic syndrome was diagnosed based on the International Diabetes Federation criteria (IDF, 2005). Data were analyzed and tested for associations between various factors using multivariate logistic regression analysis.
Results: The prevalence of metabolic syndrome was 51.17%. Age, education level, occupation, economic status, current alcohol consumption, use of antidiabetic, antihypertensive, and hypolipidemic agents, duration of psychiatric disease, and antipsychotics were significantly correlated with metabolic syndrome. The duration of psychiatric disease was a risk factor for metabolic syndrome (adjusted odds ratio = 1.055, 95%CI = 1.006 - 1.106), while exposure to agomelatine, bupropion, deanxit, tianeptine, trazodone, and vortioxetine was a protective factor for metabolic syndrome (adjusted odds ratio = 0.405, 95%CI = 0.213 - 0.772).
Conclusion: The prevalence of metabolic syndrome in this group of psychiatric patients was high. These findings support the importance of assessing and monitoring metabolic syndrome in psychiatric patients who are continuously exposured to antipsychotic every year by measuring body mass index, blood pressure, waist circumference, fasting plasma glucose, HDL cholesterol, and triglycerides.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles submitted for consideration must not have been previously published or accepted for publication in any other journal, and must not be under review by any other journal.
References
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-8.
World Health Organization. Obesity and overweight [Internet]. Geneva: WHO; 2024 [updated 2024 Mar 1; cited 2024 Mar 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
Thaihealth. World obesity day [Internet]. Bangkok: Thaihealth promotion foundation; 2023 [updated 2023 Mar 2; cited 2024 Mar 10]. Available from: https://www.thaihealth.or.th/?p=329805.
Schmitt A, Reich-Erkelenz D, Falkai P. Impact of the metabolic syndrome on severe mental disorders. Eur Arch Psychiatry Clin Neurosci 2020; 270(5): 499-500.
Berkowitz RI, Fabricatore AN. Obesity, psychiatric status, and psychiatric medications. Psychiatr Clin North Am 2011; 34(4): 747-64.
Nihalani N, Schwartz TL, Siddiqui UA, Megna JL. Weight gain, obesity, and psychotropic prescribing. J Obes 2011; 2011: 1-9.
McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic drug-related weight gain and its treatment. Am J Psychiatry 2024; 181(1): 26-38.
Gurpegui M, Martínez-Ortega JM, Gutiérrez-Rojas L, Rivero J, Rojas C, Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37(1): 169-75.
Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160(1): 112-7.
Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L'Italien G J, et al. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring) 2008; 16(4): 749-54.
Jiamjongwathana P. Metabolic syndrome in patients with major depressive disorder at department of psychiatry, Banpong hospital. Reg 4-5 Med J 2017;36(4):265-75.
Duangsa J, Sanchaisuriya P. Metabolic syndrome in patients with major depressive disorder at the outpatient clinic NakhonRatchasimaRajanagarindra Psychiatric Hospital. JBCNM 2015; 21(2): 41-58.
Kooptiwoot S, Jiamjongwathana P, Ratta-Apha W. Prevalence of metabolic syndrome in patients with major depressive disorder at outpatient clinic, Department of Psychiatry, Siriraj Hospital. J Psychiatr Assoc Thailand 2012; 57(3): 271-82.
Jantaratnotai N, Kongsakon R. Prevalence of metabolic syndrome in patients with schizophrenia spectrum disorders currently receiving clozapine at Ramathibodi hospital. J Psychiatr Assoc Thailand 2015; 60(1): 13-22.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
Alosaimi FD, Abalhassan M, Alhaddad B, Alzain N, Fallata E, Alhabbad A, et al. Prevalence of metabolic syndrome and its components among patients with various psychiatric diagnoses and treatments: a cross-sectional study. Gen Hosp Psychiatry 2017; 45: 62-9.
Prasittipatt T, Rudtanasudjatum K, Methaphat C, Thetkathuek A. Factors Influencing the abdominal obesity of employees in large-sized manufactories in the eastern region. JHS 2018; 27(5): 792-9.
Khamchata L, Dumrongpakapakorn P, Theeranut A. Metabolic syndrome: dangerous signs required management. Srinagarind Med J 2018; 33(4): 386-95.
Abbate M, Pericas J, Yañez AM, López-González AA, De Pedro-Gómez J, Aguilo A, et al. Socioeconomic inequalities in metabolic syndrome by age and gender in a Spanish working population. Int J Environ Res Public Health 2021; 18: 1-16.
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156(11): 1686-96.
Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63(5): 425-33.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71(10): 1259-72.
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry 2018; 17(3): 341-56.